![Cantos](/news-release/logo/214617/0/214617.gif?lastModified=12%2F09%2F2016%2022%3A40%3A43&size=2)
Numico -- video interviews with CEO and CFO
August 12, 2004 02:31 ET
|
Cantos
Zoetermeer, The Netherlands, Aug. 12, 2004 (PRIMEZONE) -- Numico -- second quarter and first half results. Indepth interviews available now on www.cantos.com with Jan Bennink, President and Chief...
Active Biotech - Delårsrapport januari-juni 2004
August 12, 2004 02:30 ET
|
Active Biotech
Avtal tecknat med Teva Pharmaceutical Industries avseende partnerskap för laquinimod (SAIK-MS)
TTS CD3 mot lungcancer utvecklas enligt plan
Samarbetsavtal med Strathmann Biotec för...
Scottish Power plc announces 1st Quarter Results
August 12, 2004 02:01 ET
|
Scottish Power PLC
GLASGOW, UK, Aug. 12, 2004 (PRIMEZONE) -- Scottish Power plc (NYSE:SPI) (LSE:SPI) announces 1st Quarter Results:
SCOTTISH POWER plc
2004/05 1st QUARTER RESULTS to 30 June 2004
Highlights
-...
Orkla 2. kvartal 2004
August 12, 2004 02:01 ET
|
Orkla ASA
For release content, please refer to the attachment....
Orkla second quarter 2004
August 12, 2004 02:01 ET
|
Orkla ASA
For release content, please refer to the attachment....
Femara approuvé en Suisse en tant que seul médicament homologué pour le traitement du cancer du sein à un stade précoce après traitement au tamoxifène
August 12, 2004 02:00 ET
|
Novartis Pharma AG
La Suisse est le premier pays d'Europe à approuver l'emploi de Femara dans l'extension du traitement adjuvant (après traitement au tamoxifène) chez la femme ménopauséeBâle, 12 août 2004 -...
Femara erhält in der Schweiz die Zulassung als einzige Post-Tamoxifen-Behandlung von Brustkrebs im Frühstadium
August 12, 2004 02:00 ET
|
Novartis Pharma AG
Die Schweiz ist das erste Land in Europa, das die Anwendung von Femara bei Frauen nach der Menopause im Rahmen einer erweiterten adjuvanten Behandlung im Anschluss an die Tamoxifentherapie...
Good progress for Orkla in the first half of 2004
August 12, 2004 02:00 ET
|
Orkla ASA
In comparison with the first half of 2003, Group operating profit before goodwill amortisation increased by NOK 105 million to NOK 1,226 million.
The Branded Consumer Goods business...
God fremgang for Orkla 1. halvår
August 12, 2004 02:00 ET
|
Orkla ASA
I forhold til 1. halvår i fjor viste konsernets driftsresultat før goodwillavkrivninger en økning med 105 mill. kr til 1.226 millioner kr.
Merkevareområdet hadde en fortsatt god utvikling....
New Wave Group -- Interim Report January -- June 2004
August 12, 2004 01:47 ET
|
New Wave Group
STOCKHOLM, Sweden, Aug. 12, 2004 (PRIMEZONE) -- New Wave Group:
"Continued heavy growth in sales as well as profit."
-Sales increased by 20 % to SEK 1 065 (884) million during...
- September 03, 2024 06:00 ET Deriv Celebrates 25th Anniversary with “UK’s Best Workplaces in Financial Services & Insurance™” Win
- September 03, 2024 06:00 ET Prime Intersects 9.4 gpt Gold Equivalent over 10.5 metres at Tahonitas in the Z-T Trend